Imperial College London - Charing Cross Hospital
London, Hammersmith, W6 8FS, United Kingdom
NCT Number: NCT02436200
This study will assess the benefit of a neuromuscular electrical stimulation device in patients suffering from symptoms and effects of lower limb intermittent claudication.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
London, Hammersmith, W6 8FS, United Kingdom
The circulation of blood around the body is dependent on effective pumping of the heart. Patients with claudication experience pain or discomfort in their legs usually during activity such as walking, which goes away at rest. Claudication is a symptom of peripheral arterial disease (PAD). If left untreated, patients can develop arterial insufficiency which can lead to various complications such as swelling, painful legs, reduced healing of injuries and the loss of limbs in extreme conditions.
PAD can be defined as a narrowing of the arteries reducing blood flow. It is most commonly due to atherosclerosis, and has associations with heart disease, stroke, and diabetes. Its incidence is estimated at 7-14% in the general population, increasing with age to about 20% in the over-seventies. It is associated with effects on mobility, skin condition and quality of life. Symptoms include pain in the legs on walking (intermittent claudication), pain at rest (particularly at night), gangrene, and limb loss. Management of PAD is based on encouraging exercise, and modification of risk factors such as smoking, high blood pressure, high cholesterol and diabetes.
In patients with PAD, exercise tolerance is often limited. Severe symptoms and disease can be treated by procedures such as balloon angioplasty, stenting or surgical bypass, but these procedures have risks. There also remains a percentage of patients who are not suitable for revascularisation, and have few options besides amputation available to them.
Some trials have shown that increasing the blood flow in the legs over time using medical devices (intermittent pneumatic compression, muscle stimulators), in addition to maximal medical and surgical therapy, can increase claudication distance, absolute walking distance, decrease rest pain, and reduce amputation rates. In our unit it has become apparent that there are an increasing number of medical devices available for circulatory support, either for use as an inpatient, out-patient, or a member of the general public. The supporting evidence for these is variable in scientific and clinical content or relevance, and requires clinical trials to evaluate further.
The device being used in this study, activates the pumping action of the leg muscles by providing neuromuscular electrical stimulation (NMES) to cause foot muscle contraction and relaxation. This squeezes blood back towards the heart, improving circulation.
The study will evaluate whether NMES using this device has the same beneficial effects in patients with intermittent claudication.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
Time frame: Baseline, 6 weeks
Initial walking distance measured by treadmill For the initial claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The initial claudication distance (ICD) is the distance walked until the onset of pain.
Time frame: Change in baseline treadmill walking distance at 6 weeks
For the absolute claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The absolute claudication distance (ACD) is the distance walked before the participant is forced to stop due to typical pain.
Time frame: Change in baseline femoral haemodynamics at 6 weeks
Ultrasound assessment of blood flow dynamics in the femoral artery will be obtained at rest, and if randomised to the intervention group, whilst using the device.
Time frame: Change in baseline flowmetry at 6 weeks
Optical laser flowmetry probes will be used to assess the superficial skin circulation and temperature.
Time frame: Change in baseline questionnaire scores at 6 weeks
Validated questionnaires including the Edinburgh Claudication Questionnaire and Intermittent Claudication Questionnaire will be obtained at baseline and week 6.
Time frame: Change in baseline quality of life at 6 weeks
Validated questionnaires including the Euro-Quol 5D and Short Form 36 will be measured at baseline and 6 weeks.
Time frame: Change of profile at baseline and at 6 weeks
A urine sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out.
Time frame: Change of profile at baseline and 6 weeks
A serum sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out.
Imperial College London
Other
Neuromuscular Electrical Stimulation in Patients With Intermittent Claudication
Acronym: IC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02429310
Arterial Occlusive Diseases, Arteriosclerosis
London, Hammersmith, United Kingdom
View Trial DetailsNCT02823444
Arterial Occlusive Diseases, Arteriosclerosis
Salt Lake City, Utah, United States
View Trial DetailsNCT03511157
Arterial Occlusive Diseases, Arteriosclerosis
Milwaukee, Wisconsin, United States
View Trial DetailsNCT00822172
Arterial Occlusive Diseases, Arteriosclerosis
Phoenix, Arizona, United States
View Trial Details